The first real-world analysis of the Pfizer / Bioentech corona virus vaccine claims to be consistent with its effectiveness in clinical trials, but raises serious questions about the UK’s decision to delay the second dose.
Scientists in Israel – it plays a leading role COVID-19 Vaccine breed – Sky News read initial data from 200,000 vaccinators and said it was “very optimistic”.
They mainly say that their results did not show more performance than what the UK used to justify the second level delay of Pfizer / Bioendech Jabin.
Professor Ron Poliser is a physician, epidemiologist and chief discoverer for Glitz, Israel’s largest health care provider. He is also a consultant to the World Health Organization.
“We compared 200,000 people over the age of 60 who were vaccinated. We took a comparison team of 200,000 people of the same age who were not vaccinated, and they fit this group with different variations …” Professor Poliser said.
“Then we looked at what the daily positive rate was … and we found that there was no difference between vaccination and vaccination until the 14th day after vaccination.
“But on the 14th day after vaccination, there was a 33% positive drop in the vaccinated group, but not in the undiagnosed group … which is really good news.”
However, UK scientists said in December Experimental data suggested that it was 89% effective After a dose.
Document issued by the Joint Committee on Vaccination and Immunization, Vaccine Advisers, Government of the United Kingdom Justify delaying the second dose by up to 12 weeks He said: “Using data for events observed between days 15 and 21, the efficacy against symptomatic COVID-19 was estimated at 89%, which suggests that short-term protection from dose 1 from the 14th day of vaccination was the highest.”
This is more promising than the new real world Israeli data suggests.
Responding to the UK government strategy, Professor Poliser said: “We have the data and ratings I have given.
“We did not see a reduction of 89% in the data we reported. Further data and analyzes will be published in the form of a co-reviewer science.”
He added: “The practice in Israel is to give a second vaccine every three weeks.
“So I can’t say what the impact of not giving the second dose is …”
Israel follows the Pfizer / Bioentech protocol Corona virus Vaccinate after the first three weeks.
It has a small population and regular distribution from Pfizer / Bioendech. In return it provides detailed data to Pfizer.
In contrast, the UK with the largest population prefers the first jab – arguing that a dose given to as many people as possible is better than two to less jabs.
“We have already covered 25% of our population and over 75% over the age of 60 in the last four and a half weeks.
“Therefore, we are one of the first countries in the world to see the full impact of preventing such a large number of vaccines in large numbers,” said Professor Poliser.
“By being able to handle this data in real time, clean it up, and use the right epidemiological method, we are now able to provide answers to the most pertinent questions.”
Israeli scientists believe their number will rise to 33% when data is compiled from young people, and that data real life boosts their confidence.
“This is not the best system for a randomized control test where everything from training maintenance to people of choice is done very meticulously.
“This is the real world. So, looking at the real world impact in the same direction so quickly and at the same time we saw it in clinical trials is something that gives us so much hope.”
Tel Aviv Sou Rusky Hospital, one of hundreds of vaccination centers, vaccines hundreds of people every hour.
Ronnie Kamsu is the director of the hospital. He served as the government’s “corona jar” – a rotating advisory role – until last month.
“I believe, I really believe, that this is the beginning of the end because the vaccine builds immunity.
“We see it clearly, and we see a change in people suffering from serious illness Corona virus And mild disease. Those who have been vaccinated are more secure, ”said Professor Kamsu.
When asked about the UK strategy of delaying the second level, 89% seemed “very optimistic”, but understood why compromises had to be made.
“If you’ve been short on vaccines, this is a good idea … If you take a booster shot, we hope you still have an effect after six weeks, and the effect is gradually growing.
“We’re not sure if it’s 21 days for Pfizer and 28 days for Moderna, but there’s a clear logic behind postponing it when you reduce vaccines.”
In an earlier report on this result, JCVI stated: “With most vaccines the extended interval between main and booster doses leads to better immunity to the booster dose.
“There is evidence that the long interval between the first and second doses promotes strong immunity with the AstraZeneca vaccine.
“There is currently no strong evidence that the immune response from the Pfizer-Bioentech and Astrogene vaccines differs significantly from each other.
“The panel initially advised to prioritize the administration of the first vaccine because it would have a greater public health impact in the short term and reduce the number of preventable deaths from COVID-19.”
Contact Sky News Pharmaceuticals and Health Products Regulatory Agency for feedback.